About this course

Several SARS-CoV-2 virus variants have emerged since the pandemic started. Alongside the threat of these emerging variants, the evidence for COVID-19 therapeutics has likewise grown.

In the last two years alone, several medications have been shown to prevent hospitalization among vulnerable groups who have non-severe COVID-19 infection. However, guidelines continue to change as some drugs are deemed ineffective for emerging COVID subvariants. This e-learning module reviews the most recent outpatient medications recommended by the WHO for non-severe COVID-19 infection, the mechanism of action of these drugs, their adverse effects, and summarizes the available evidence regarding these therapeutic options.

Learning outcomes

Upon completion of the educational activity, participants will be able to

Identify the most recent outpatient medications recommended by the WHO for non-severe COVID-19 infection

Understand the mechanism of action of these drugs, their adverse effects, indications, and contraindications

Review the available evidence regarding these therapeutic options

Topics covered

Introduction

WHO COVID-19 severity definitions

Identifying patients at risk for hospitalization

Risk factors for severe COVID-19 outcomes

Recommended action points for management

Active monitoring, preventive measures

Consider therapeutic options

Overview of outpatient medications

Antivirals: Nirmatrelvir-Ritonavir, Remdesivir, Molnupiravir

Monoclonal antibodies: Bamlanivimab-Etesevimab, Bebtelovimab, Casirivimab-Imdevimab, Sotrovimab

Current WHO recommendations

Recent updates

0.5 CPE Point Available

Score at least 80% on the quiz.

A certificate can be downloaded upon successful completion. Please use the information on the certificate to claim your CPE points.